Lv2
130 积分 2024-02-01 加入
Health state utilities in patients with advanced non-small-cell lung cancer in China
29天前
已完结
Health state utilities in non–small cell lung cancer: An international study
29天前
已完结
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
1个月前
已完结
Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis
1个月前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
1个月前
已完结
Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
1个月前
已完结
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
1个月前
已完结
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
1个月前
已完结
Elevated respiratory complications following robotic-assisted lobectomy: A national cohort analysis of 26,140 cases
3个月前
已关闭
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
3个月前
已完结
皖公网安备34019202002308
